Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chemokine (C-X-C motif) ligand 13 (CXCL13)
- Target
- CXCL13
- Molecular classification
- Chemokine, Cytokine, Secreted protein
01
Overview
Chemokine (C-X-C motif) ligand 13 (CXCL13) is a small secreted chemokine involved in B lymphocyte chemotaxis and organization of B cells within lymphoid follicles. CXCL13 interacts with its receptor, CXCR5, to selectively attract B cells to particular tissues, influencing the structure and function of secondary lymphoid organs. CXCL13 expression serves as a biomarker for certain lymphoid malignancies and autoimmune conditions, and elevated levels have been linked to disease activity and prognosis in idiopathic pulmonary fibrosis and some cancers. Although direct drug targeting is not yet clinically available, modulating the CXCL13 axis is an active research area, with implications for treating immune-driven diseases. Safety considerations for future therapies include monitoring for immune dysfunction and unwanted effects on lymphoid tissue architecture.
- Other names
- B lymphocyte chemoattractant (BLC)B cell-attracting chemokine 1 (BCA-1)
02
Mechanism of action
Antagonism or blockade of CXCL13-CXCR5 interaction to reduce B cell migration and infiltration in disease; Modulation of immune microenvironment
03
Biological functions
Chemotaxis of B lymphocytesOrganization of B cells in lymphoid folliclesRegulation of immune responses, particularly in secondary lymphoid tissuesBiomarker of germinal center T cell (T follicular helper cell)
04
Disease associations
InflammationCancer (e.g., lymphomas, follicular dendritic cell sarcoma)Autoimmune diseasePulmonary disease (idiopathic pulmonary fibrosis, COPD)Infection (roles in immune response to influenza)
05
Safety considerations
Potential risk for immune suppression, altered lymphoid tissue architecture, and off-target effects in therapies targeting CXCL13Therapeutic blockade may impair humoral immune responses
06
Interacting drugs
No approved drugs directly target CXCL13, but experimental treatments that modulate B cells or the CXCL13-CXCR5 axis are under investigation for autoimmune and inflammatory diseases
07
Biomarkers
CXCL13 plasma and tissue levels as a prognostic biomarker for disease activity and outcomes in idiopathic pulmonary fibrosis and lymphomasMarker for T follicular helper cell phenotype in lymphomas
Beyond the preview
Go deeper on Chemokine (C-X-C motif) ligand 13 (CXCL13).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chemokine (C-X-C motif) ligand 13 (CXCL13).